Elevated tissue expression of RANKL and RANK is associated with poorer survival rates in pancreatic cancer patients.

Autor: Ortega MA; Department of Medicine and Medical Specialities, Faculty of Medicine and Health Sciences, University of Alcalá, Alcala de Henares, Madrid, Spain. miguelangel.ortega@uah.es.; Ramón y Cajal Institute of Sanitary Research (IRYCIS), Madrid, Spain.; Cancer Registry and Pathology Department, Principe de Asturias University Hospital, Alcala de Henares, Madrid, Spain., Jiménez-Álvarez L; Department of Medicine and Medical Specialities, Faculty of Medicine and Health Sciences, University of Alcalá, Alcala de Henares, Madrid, Spain.; Department of General and Digestive Surgery, General and Digestive Surgery, Príncipe de Asturias Teaching Hospital, Alcala de Henares, Madrid, Spain., Fraile-Martinez O; Ramón y Cajal Institute of Sanitary Research (IRYCIS), Madrid, Spain.; Department of Medicine and Medical Specialities, Faculty of Medicine and Health Sciences, University of Alcalá, Alcala de Henares, Madrid, Spain. oscarfra.7@hotmail.com., Garcia-Montero C; Ramón y Cajal Institute of Sanitary Research (IRYCIS), Madrid, Spain.; Department of Medicine and Medical Specialities, Faculty of Medicine and Health Sciences, University of Alcalá, Alcala de Henares, Madrid, Spain., De León-Oliva D; Ramón y Cajal Institute of Sanitary Research (IRYCIS), Madrid, Spain.; Department of Medicine and Medical Specialities, Faculty of Medicine and Health Sciences, University of Alcalá, Alcala de Henares, Madrid, Spain., Toledo-Lobo MDV; Ramón y Cajal Institute of Sanitary Research (IRYCIS), Madrid, Spain.; Unit of Cell Biology, Department of Biomedicine and Biotechnology, University of Alcala, Alcala de Henares, Madrid, Spain., Palacios E; Inari Biotech S.L., Madrid, Spain., Granado P; Inari Biotech S.L., Madrid, Spain., Esteban A; Inari Biotech S.L., Madrid, Spain., Guijarro LG; Ramón y Cajal Institute of Sanitary Research (IRYCIS), Madrid, Spain.; Unit of Biochemistry and Molecular Biology, Department of System Biology (CIBEREHD), University of Alcalá, Alcala de Henares, Spain., Pekarek L; Ramón y Cajal Institute of Sanitary Research (IRYCIS), Madrid, Spain.; Oncology Service, Guadalajara University Hospital, Guadalajara, Spain., Asúnsolo Á; Department of Surgery, Medical and Social Sciences, Faculty of Medicine and Health Sciences, University of Alcalá, Alcala de Henares, Madrid, Spain.; Department of Epidemiology and Biostatistics, Graduate School of Public Health and Health Policy, University of New York, New York, NY, United States., López-González L; Ramón y Cajal Institute of Sanitary Research (IRYCIS), Madrid, Spain.; Department of Surgery, Medical and Social Sciences, Faculty of Medicine and Health Sciences, University of Alcalá, Alcala de Henares, Madrid, Spain., Bujan J; Ramón y Cajal Institute of Sanitary Research (IRYCIS), Madrid, Spain.; Department of Medicine and Medical Specialities, Faculty of Medicine and Health Sciences, University of Alcalá, Alcala de Henares, Madrid, Spain., García-Honduvilla N; Ramón y Cajal Institute of Sanitary Research (IRYCIS), Madrid, Spain.; Department of Medicine and Medical Specialities, Faculty of Medicine and Health Sciences, University of Alcalá, Alcala de Henares, Madrid, Spain., Álvarez-Mon M; Ramón y Cajal Institute of Sanitary Research (IRYCIS), Madrid, Spain.; Department of Medicine and Medical Specialities, Faculty of Medicine and Health Sciences, University of Alcalá, Alcala de Henares, Madrid, Spain.; Immune System Diseases-Rheumatology, Oncology Service and Internal Medicine (CIBEREHD), University Hospital Príncipe de Asturias, Alcala de Henares, Madrid, Spain., Saez MA; Ramón y Cajal Institute of Sanitary Research (IRYCIS), Madrid, Spain.; Department of Medicine and Medical Specialities, Faculty of Medicine and Health Sciences, University of Alcalá, Alcala de Henares, Madrid, Spain.; Pathological Anatomy Service, Central University Hospital of Defence-UAH Madrid, Alcala de Henares, Madrid, Spain., Díaz-Pedrero R; Ramón y Cajal Institute of Sanitary Research (IRYCIS), Madrid, Spain.; Department of General and Digestive Surgery, General and Digestive Surgery, Príncipe de Asturias Teaching Hospital, Alcala de Henares, Madrid, Spain.; Department of Epidemiology and Biostatistics, Graduate School of Public Health and Health Policy, University of New York, New York, NY, United States.
Jazyk: angličtina
Zdroj: Histology and histopathology [Histol Histopathol] 2024 Sep; Vol. 39 (9), pp. 1133-1140. Date of Electronic Publication: 2023 Dec 29.
DOI: 10.14670/HH-18-700
Abstrakt: Pancreatic cancer is a highly lethal malignancy with a growing incidence reported worldwide. Pancreatic ductal adenocarcinoma (PDAC) is the most common type of pancreatic cancer, which is often diagnosed at advanced stages, making its prognosis and medical management difficult. The identification of histopathological biomarkers has allowed a more precise stratification of pancreatic cancer patients, providing additional information about their prognosis and offering possible therapeutic targets to be explored. The prognostic value of the receptor activator of nuclear factor-kappa B (RANK) and its ligand (RANKL) has been evaluated in breast and prostate tumors, however, their usefulness has not been assessed in pancreatic cancer. In the present work, we analyzed the relationship between the protein expression of RANK and RANKL with the survival of 41 patients with pancreatic cancer followed for 60 months, by performing immunohistochemistry and Kaplan-Meier curves. Our results demonstrate a direct association of high expression levels of RANK and RANKL with poorer survival of pancreatic cancer patients in comparison to those with low/medium and null expression levels of both markers. Further studies should be conducted to explore the carcinogenic role of both components in this type of tumor, as well as additional promising translational uses.
(©The Author(s) 2023. Open Access. This article is licensed under a Creative Commons CC-BY International License.)
Databáze: MEDLINE